ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 31 Aug 2022
Last Updated on 31 Aug 2022
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Nivolumab 40 mg/4 mL, 100 mg/10 mL and 240 mg/24 mL concentrate for solution for infusion for:
    • Adjuvant treatment of completely resected oesophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy. Maximum treatment duration is 12 months.
    • Untreated, unresectable advanced or metastatic HER2 negative gastric cancer, GEJ cancer or oesophageal adenocarcinoma when used with fluoropyrimidine and platinum-based chemotherapy. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses.
    • Treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for this condition in the unresectable advanced, recurrent or metastatic setting.

Funding status

Nivolumab 40 mg/4 mL, 100 mg/10 mL and 240 mg/24 mL concentrate for solution for infusion are recommended for inclusion on the Cancer Drug List (Medication Assistance Fund and MediShield Life monthly claim limit of SG$1800) for the abovementioned indications from 1 September 2022.


Nivolumab for treating gastroesophageal cancers (31 Aug 22) Nivolumab for treating gastroesophageal cancers PES (31 Aug 22)